ID Biomedical Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ID Biomedical Corp.
The latest drug development news and highlights from our US FDA Performance Tracker.
Pfizer gains full approval for its lung cancer treatment Xalkori, following accelerated approval in 2011; also updates on ID Biomedical’s adjuvanted H5N1 flu vaccine; a new indication for Bayer/Onyx’s cancer treatment Nexavar; a new formulation for Merck’s antifungal Noxafil; and BTG’s new varicose vein product Varithena.
About one-third of the influenza B viruses tested this year are from the strain not included in this season’s trivalent vaccine; GlaxoSmithKline’s Fluarix is the second approved seasonal flu vaccine to protect against four virus strains, and by next season half of the U.S. manufacturers could be offering a broader spectrum product.
FDA encourages people to get vaccinations since two of the three virus strains in this season’s flu vaccines differ from last season’s; several manufacturers plan to distribute slightly fewer doses in 2012-2013 than in the prior year.
- Research, Analytical Equipment & Supplies
- Drug Delivery